|Swedish Orphan Biovitrum AB -- USA Stock|| |
USD 14.72 0.0005 0.0034%
Vice President Head of Drug Design and Development
Mr. Stephen James serves as Vice President, Head of Drug Design and Development at Swedish Orphan Biovitrum AB . He was employed by the Company since 2001. He previously held a number of management positions in Research and PreClinical Development in Pharmacia Upjohn, Pharmacia AB and Biovitrum AB. Prior to this, he served as University of Dundee Research Fellow, the United Kingdom. He holds a Doctorate of Philosophy degree in Biochemistry and Cell Biology from the University of Leeds, and a BS degree in Biochemistry and Microbiology from the University of St. Andrews.
Age: 49 Ph.D
46 86 97 20 00 http://www.sobi.com
The company has return on total asset (ROA)
of 5.92 %
which means that it generated profit of $5.92 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 11.34 %
meaning that it generated $11.34 on every $100 dollars invested by stockholders.
The company has accumulated 60.4 M in total debt with debt to equity ratio (D/E) of 8.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.69 which is within standard range for the sector.
Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.